Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$101.88 USD

101.88
10,180,742

-0.44 (-0.43%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $101.93 +0.05 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Merck vs. Pfizer: Which Stock Looks Better Post-Earnings?

Pfizer is better positioned than Merck and thus calls for investors' attention post earnings.

    Stock Market News for May 03, 2017

    Benchmarks finished in the green on Tuesday following the release of strong earnings reports

      Drug Stock Q1 Earnings Releases on May 4: ZTS, REGN & More

      Here we have four pharma companies that are set to report first-quarter results on May 4. Let's see how things are shaping up for them.

        Pfizer (PFE) Q1 Earnings Beat, Sales Lag, 2017 View Intact

        Pfizer, Inc. (PFE) reported first-quarter 2017 adjusted earnings per share of 69 cents, which beat the Zacks Consensus Estimate of 67 cents by 3%.

          Ekta Bagri headshot

          Merck (MRK) Beats on Earnings in Q1, Ups view

          Merck surpassed first-quarter 2017 earnings expectations. The company reported EPS of 88 cents while our consensus called for EPS of 83 cents.

            Tracey Ryniec headshot

            This Week's Most Spectacular Earnings Charts

            Tracey went through all of the earnings charts to find the best so you don't have to.

              Arpita Dutt headshot

              6 FDA Events to Watch Out for in May 2017

              Here is a look at a few important regulatory events scheduled for the month of May including the FDA's decision regarding the label expansion of Merck's (MRK) Keytruda.

                Seattle Genetics (SGEN) Q1 Loss Widens, Sales Top Estimates

                Seattle Genetics, Inc. (SGEN) reported a loss of 42 cents per share for the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 41 cents and the year-ago loss of 15 cents per share.

                  Bristol-Myers (BMY) Beats on Q1 Earnings, Ups 2017 View

                  Bristol-Myers Squibb Company's (BMY) first-quarter 2017 earnings of 84 cents per share beat the Zacks Consensus Estimate of 72 cents and surged 14% from the year-ago period.

                    What's in Store for Merck (MRK) this Earnings Season?

                    Merck & Co., Inc. (MRK) will be reporting first-quarter 2017 earnings on May 2, before market opens. Last quarter, the company delivered a positive earnings surprise of 1.14%.

                      Bristol-Myers (BMY) to Post Q1 Earnings: What's in Store?

                      Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Apr 27, before the opening bell.

                        What's in Store for Agenus (AGEN) this Earnings Season?

                        Agenus Inc. (AGEN) is expected to report first-quarter 2017 results later this month or early next month.

                          Arpita Dutt headshot

                          3 Key Factors to Look Out for in Biogen's Q1 Results

                          With Biogen (BIIB) set to report Q1 results tomorrow, here is a look at 3 key factors investors will be focused on apart from earnings and revenue.

                            The Zacks Analyst Blog Highlights: Berkshire Hathaway, Oracle, Merck, Honeywell and Altria

                            The Zacks Analyst Blog Highlights: Berkshire Hathaway, Oracle, Merck, Honeywell and Altria

                              J&J (JNJ) Q1 Earnings Beat Estimates, Pharma Sales Slow Down

                              Johnson & Johnson (JNJ) reported mixed first quarter results, with earnings beating expectations while sales missing the same.

                                Zoetis (ZTS) Inks Agreement to Acquire Nexvet Biopharma

                                Zoetis Inc. (ZTS) announced an agreement to buy Nexvet Biopharma plc (NVET) for an aggregate equity valuation of approximately $85 million

                                  Swarup Gupta headshot

                                  Dow 30 Stock Roundup: Microsoft Buys Cloud Tech Firm, Disney's "Beauty and the Beast"

                                  The index experienced an eventful and holiday shortened week, marked by growing geopolitical tensions.

                                    Bristol-Myers (BMY) Collaborates with Apexigen for Opdivo

                                    Bristol-Myers Squibb Company (BMY) announced a collaboration agreement with clinical-stage biopharmaceutical company Apexigen, Inc.

                                      Inovio's Ebola Vaccine Positive in Expanded Phase I Study

                                      Inovio Pharmaceuticals, Inc. (INO) recently reported positive preliminary results from the expanded stage of its phase I study, EBOV-001.

                                        Bristol-Myers' (BMY) sBLA For Opdivo Accepted by the FDA

                                        Bristol-Myers Squibb Company (BMY) recently announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) for the label expansion of immune-oncology drug Opdivo.

                                          Agenus (AGEN) Sharpens Focus on Drug Development Programs

                                          We issued an updated report on Agenus Inc. (AGEN) on Apr 4.

                                            5 Reasons to Invest in Eli Lilly (LLY) Stock Right Now

                                            Lily carries a Zacks Rank #2 (Buy).

                                              Bristol-Myers (BMY), Incyte to Advance Clinical Program

                                              Bristol-Myers Squibb Company (BMY) and Incyte Corporation (INCY) recently announced that the companies will advance their clinical development program.

                                                Kite Pharma Completes Filing for CAR-T Therapy with FDA

                                                Kite Pharma, Inc. (KITE) announced that it has completed the filing of a rolling submission of the Biologics License Application (BLA) for its lead pipeline candidate, axicabtagene ciloleucel to the FDA.

                                                  Bristol-Myers (BMY) Opdivo Gets Positive CHMP Opinion

                                                  Bristol-Myers Squibb Company (BMY) announced that the CHMP has recommended the approval of immunotherapy Opdivo as monotherapy for the treatment of squamous cell cancer of the head and neck (SCCHN) in adults.